Regeneron Pharmaceuticals Inc. diskutieren

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1,250.00 price target on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1,282.00 price target on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $1,200.00 price target on the stock.

Hey there! So, I've been keeping an eye on Regeneron Pharmaceuticals, and I gotta say, I'm pretty impressed. Their latest data on drugs like EYLEA HD and Dupixent is looking solid. These treatments are showing some real promise in areas like eye diseases and chronic hives. And let's not forget about Libtayo - it's making waves in lung cancer treatment. The company's innovative approach and strong pipeline make me think they've got room to grow. Sure, there are always risks in biotech, but Regeneron seems to be firing on all cylinders right now. With their current price around $973, I reckon there's potential for it to hit $1050 in the near future. What do you think? Are you as excited about Regeneron as I am?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,200.00 price target on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $1,300.00 price target on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Royal Bank of Canada from $1,282.00 to $1,252.00. They now have an "outperform" rating on the stock.